title: Pioglitazone Use and Risk of Bladder Cancer--Reply.
authors.affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California.
authors.forename: Assiamira
authors.initials: A
authors.lastname: Ferrara
authors.affiliation: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia.
authors.forename: James D
authors.initials: JD
authors.lastname: Lewis
authors.affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California.
authors.forename: Laurel A
authors.initials: LA
authors.lastname: Habel
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D010190:Pancreatic Neoplasms / Q000139:chemically induced*; D011471:Prostatic Neoplasms / Q000139:chemically induced*; D045162:Thiazolidinediones / Q000009:adverse effects*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones